Drug Profile
Research programme: interleukin-1 receptor associated kinase inhibitors - Rigel Pharmaceuticals
Alternative Names: IRAK1/4 inhibitors - Rigel Pharmaceuticals; IRAK4 kinase inhibitors - Rigel Pharmaceuticals; R 191Latest Information Update: 25 Nov 2021
Price :
$50
*
At a glance
- Originator Rigel Pharmaceuticals; University of Texas M. D. Anderson Cancer Center
- Class Antineoplastics
- Mechanism of Action Interleukin-1 receptor-associated kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Chronic myelomonocytic leukaemia; Haematological malignancies; Myelodysplastic syndromes